Understanding AMD and New Therapies for GA

Tracking # 20-949768

Price not reported

There are no ratings for this course

Learn more

Educator REVIEW EDUCATION GROUP

CE Broker Reporting Reported automatically

Method Lecture

Dates Contact provider

Course overview

This course will discuss Dry Age Related Macular Degeneration and the potential new therapies to help slow the progression of geographic atrophy(GA). Historically, there have been no proven therapeutic interventions for geographic atrophy. And yet, patients will continue to lose vision due to growing GA. However, there are many new potential treatments in the pipeline for FDA approval for the treatment of GA. Biomarkers for GA will be discussed with a closer look at color fundus photos, OCT and FAF imaging. Through this course, the audience will learn about the pathophysiology of GA, including the complement cascade, to better understand the potential future therapeutics for GA control. Non-complement therapies for GA will also be discussed including oral anti-inflammatory, intravitreal cytoprotective and neuroprotective agents, gene therapy and stem cell transplantation. Optometry will be on the forefront of diagnosing and referring patients for appropriate treatment as these new therapeutics become available.

Subject areas

This course counts toward the state boards and subject areas below.

Texas Optometry Board

Optometrist

1h Diagnostic / Therapeutic

Disclosure statements

I have read and will comply with the COPE requirements for course qualification. I further

agree to notify COPE in writing should any information provided, including financial/proprietary

information, change at any time during the three year qualification period of this course.

I agree that I will keep my presentation free from commercial interest or bias. I will maintain

independent control over the content of my presentation, so that it is balanced, objective,

presented with scientific rigor and not be for the purpose of promoting products, equipment,

etc. (Therefore, my presentation should not be perceived by attendees as a commercial.) I

further agree that I will not change the basic content of my presentation following approval.

I agree to disclose to the audience the existence of any significant financial/professional

relationships with the manufacturer(s) of any commercial product(s) and/or the provider(s) of

any commercial service(s) discussed in the educational presentation. (Said relationships can

include such things as grant/research support, employment, consulting and/or speakers bureau

arrangements, major stock ownership, etc.) I will disclose any of these relationships, whether

or not there is direct commercial support for the CE activity. This disclosure is made to provide

the audience the information on which they can make judgments as to a presenter’s objectivity.

I agree to disclose the attendees; a) when products or procedures being discussed are off label,

unlabeled, experimental, and/or investigational (not FDA approved); b) any limitations on the

information that is presented, such as data that are preliminary or that represent ongoing

research, interim analyses, and/or unsupported opinion.

I agree I have an ethical responsibility to make appropriate decisions related to my

presentation, and all issues involving financial remuneration.